5485 Rue Pare
Montreal, QC H4P 1P7
Full Time Employees:
|Mr. Paul Baehr||Pres, CEO & Chairman||434.09k||N/A||1943|
|Belinda Franco C.A., CPA||CFO, VP of Fin. & Admin. and Sec.||303.33k||N/A||N/A|
|Mahendra Kumar Pallapothu||VP of Operations||432.21k||N/A||N/A|
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.
IBEX Technologies Inc.’s ISS Governance QualityScore as of February 1, 2023 is 3. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 1; Compensation: 1.